Telix has announced that it intends to acquire TheraPharm, a company developing radiopharmaceutical and diagnostic solutions for disorders of the blood and bone marrow. TheraPharm has developed the anti-CD66 antibody besilesomab, which has diagnostic and therapeutic applications for osteomyelitis, hematopoietic stem cell transplant (HSCT), and the rare disease systemic amyloid light-chain amyloidosis (SALA).Den vollständigen Artikel lesen ...
© 2020 Edison Investment Research